NCT04399395View on ClinicalTrials.gov

Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 1, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

December 31, 2022

Conditions
Obesity
Interventions
DRUG

Naltrexone/bupropion

Approved drug for obesity treatment

OTHER

Lifestyle

Lifestyle

Sponsors
All Listed Sponsors
collaborator

Orexigen Therapeutics, Inc

INDUSTRY

lead

Oslo University Hospital

OTHER